| Authors: |
Avet-Loiseau H; Unité de Genomique du Myélome, Institut National de la Santé et de la Recherche Médicale, University Cancer Center of Toulouse, Toulouse, France., Davies FE; Perlmutter Cancer Center, NYU Langone Health, New York, NY., Samur MK; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA., Corre J; Unité de Genomique du Myélome, Institut National de la Santé et de la Recherche Médicale, University Cancer Center of Toulouse, Toulouse, France., D'Agostino M; Division of Hematology, AOU Città della Salute e della Scienza di Torino, Torino, Italy.; University of Torino and Department of Molecular Biotechnology and Health Sciences, Torino, Italy., Kaiser MF; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom., Raab MS; Department of Medicine V, Heidelberg Myeloma Center, University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany., Weinhold N; Department of Medicine V, Heidelberg Myeloma Center, University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany., Gutierrez NC; Departamento de Hematología, Hospital Universitario de Salamanca, (HUSA/IBSAL), Centro de Investigación del Cáncer-IBMCC (CSIC/USAL), CIBERONC, Salamanca, Spain., Paiva B; Cancer Center Clínica Universidad de Navarra (CCUN), Centro de Investigación Médica Aplicada (CIMA LAB Diagnostics), IDISNA, CIBERONC, Pamplona, Spain., Neri P; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada., Weisel K; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Maura F; Division of Myeloma, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL., Walker BA; Division of Hematology and Oncology, School of Medicine, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Indianapolis, IN., Bustoros M; Division of Hematology and Medical Oncology, Joan and Sanford I. Weill Department of Medicine, Sandra & Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY., Stewart AK; Division of Hematology-Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Usmani SZ; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Hillengass J; Department of Medicine-Myeloma, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Chng WJ; Department of Medical Oncology, National University Cancer Institute, and Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore., Keats JJ; Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, AZ., Martinez-Lopez J; Hospital 12 de Octubre, i+12, School of Medicine Universidad Complutense, CNIO, Madrid, Spain., Sperling AS; Dana-Farber Cancer Institute, Boston, MA., Touzeau C; Hematology Department, University Hospital Hôtel-Dieu, Nantes, France., Zhan F; Department of Internal Medicine, Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR., Raje NS; Department of Hematology/Oncology, Center for Multiple Myeloma, Harvard Medical School, Massachusetts General Hospital, Boston, MA., Cavo M; Dipartimento di Scienze Mediche e Chirurgiche, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Università di Bologna, Bologna, Italy., Bolli N; Department of Oncology and Onco-Hematology, University of Milan and Hematology Section Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Ghobrial IM; Department of Medical Oncology, Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Dhodapkar MV; Emory University School of Medicine, Atlanta, GA., Jagannath S; Icahn School of Medicine at Mount Sinai, New York, NY., Spencer A; Department of Haematology, The Alfred Hospital and Monash University, Melbourne, Australia., Parekh S; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY., Bahlis NJ; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada., Lonial S; Winship Cancer Institute, Emory University, Atlanta, GA., Sonneveld P; Department of Hematology, EMN/Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Bergsagel L; Division of Hematology, Mayo Clinic, Phoenix, AZ., Orlowski RZ; Departments of Lymphoma/Myeloma and Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Morgan G; Perlmutter Cancer Center, NYU Langone Health, New York, NY., Mateos MV; Departamento de Hematología, Hospital Universitario de Salamanca, (HUSA/IBSAL), Centro de Investigación del Cáncer-IBMCC (CSIC/USAL), CIBERONC, Salamanca, Spain., Rajkumar SV; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN., San Miguel JF; Cancer Center Clínica Universidad de Navarra (CCUN), CIMA, CIBERONC, IDISNA, Pamplona, Spain., Anderson KC; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA., Moreau P; Hematology Department, University Hospital Hôtel-Dieu, Nantes, France., Kumar S; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN., Prósper F; Hematology and Cell Therapy and Program of Hematology-Oncology CIMA, Clinica Universidad de Navarra, IdISNA, CIBERONC, Pamplona, Spain., Munshi NC; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA. |
